| DB ID | MyCo_5942 |
| Title | Free circulating mircoRNAs support the diagnosis of invasive aspergillosis in patients with hematologic malignancies and neutropenia |
| Year | 2020 |
| PMID | 33020578 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | Hematologic malignancies and neutropenia |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study protocol was approved by the ethics committee of the University Hospitals of Debrecen, Hungary (MK-JA/50/0096-01/2017) and carried out in accordance with the approved guidelines. In the case of postmortem histology informed consent was obtained from the donor’s next of kin. Written consent was obtained from all participants. Measuring of miRNA expression levels were performed in parallel with Aspergillus GM-EIA. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | miR-142-3p |
| Biomarker Full Name | miR-142-3p |
| Biomarker Type | Diagnostic |
| Biomolecule | miRNA |
| Geographical Location | Hungary |
| Cohort | This retrospective case–control study was performed from May 2017 to February 2019, involving two hematology centers in Hungary: University of Debrecen, Faculty of Medicine, Institute of Internal Medicine, Debrecen, Hungary (C1) and Institute of András Jósa County and Teaching Hospital, Division of Hematology, Nyíregyháza, Hungary (C2). Patient population comprised 40 adult admissions; 26 males with the median age of 52 (range 21–83) and 14 females with the median age of 54 (range; 24–83) having different hematological malignancies (mainly acute leukemia—42%) receiving stem cell transplantation and intensive chemotherapy (neutrophil count < 0.5×109 cells/L). Patients developingneutropenic fever (NF); tem-perature > 38 °C of fever recorded twice or > 38.5 °C recorded once were recruited with two exceptions (P2, P36). Children < 17 years were excluded from the study. There were 15 healthy controls included with no previous history of onco-hematology (OH) diseases or SIRS with the median age of 42.5 (range 24–75). |
| Cohort No. | 40 Patients and 15 control |
| Age Group | 21-83 |
| P Value | p<0.005 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | 1.1 fold |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) can be frequently associated mainly with acute myeloid and lymphoid (AML, ALL) leukemia and occurs primarily in the ¬ lung. The well-established risk factors include underlying malignancy, immunosuppression and profound ¬ neutropenia. Without timely initiated antifungal therapy the mortality of IA related hospitalization can top 70%, whereas in bone-marrow transplant patients, it has been reported to be even ¬ higher. As a result of prolonged hospital stay, the burden of aspergillosis-related IFDs remains an immense public health problem, with an estimated treatment cost above $600 million/year in the ¬ US. |
| Technique | PCR |
| Analysis Method | tetramiR assay [TaqMan quantitative real-time PCR (miRNA assay)] |
| ELISA kits | Platelia™ Aspergillus Ag Kit (BioRad Laboratories, Hungary) |
| Assay Data | None |
| Validation Techniques used | tetramiR assay [TaqMan quantitative real-time PCR (miRNA assay)], Platelia Aspergillus GM-eiA, Histology |
| Up Regulation Down Regulation | Up regulated |
| Sequence Data | None |
| External Link | None |
